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Double-hit primary unilateral adrenal lymphoma with good outcome
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Abstract
Introduction. Primary adrenal non-Hodgkin’s lymphoma
(NHL) is a rare neoplasm with poor prognosis. On the
other side, double-hit lymphomas with BCL2 and MYC
translocation are characterized by advanced disease stage,
extranodal and central nervous system involvements at
presentation or disease progression. Case report. We re-
ported a 73-year-old male patient with double-hit primary
adrenal lymphoma and preserved adrenal function, showing
a favorable clinical course. Computed tomography of ab-
domen showed a 9 u 7 cm mass of the left adrenal gland.
Laparatomy with left adrenalectomy was done and his-
tological examination revealed diagnosis of a diffuse large
B-cell NHL (DLBCL), non-GCB subtype. The patient was
treated with 6 cycles of R-CHOP chemotherapy with re-
duced doses of doxorubicin because of the decreased left
verticle ejection fraction. The patient was followed up
regularly for 20 months with no evidence of tumor recur-
rence despite the inherently poor prognostic profile and
double-hit phenotype of the disease. Conclusion. R-CHOP
chemotherapy in combination with adrenalectomy can be
an effective first-line regimen for primary adrenal DLBCL,
despite the inherently poor prognostic profile (non-GCB
subtype, bulky disease, elevated lactate dehydrogenase and
double-hit phenotype of the disease).
Key words:
lymphoma, non-hodkin; adrenal gland neoplasms;
drug therapy; surgical procedures, operative;
prognosis.
Apstrakt
Uvod. Primarni adrenalni nehoÿkinski limfom izuzetno je re-
dak oblik limfoma i odlikuje se lošom prognozom. Sa druge
strane, double-hit limfomi sa BCL2 i MYC translokacijom ka-
rakterišu se uznapredovalom bolešýu u vreme postavljanja
dijagnoze,  ÿesto prisutnom ekstranodalnom lokalizacijom
bolesti i lošom prognozom. Prikaz bolesnika. Prikazali smo
bolesnika starog 73 godine sa double-hit primarnim limfomom
nadbubrega sa oÿuvanom adrenalnom funkcijom i povoljnim
kliniÿkim tokom. Kompjuterizovanom tomografijom abdo-
mena registrovana je tumorska promena leve adrenalne žlez-
de, veliÿine 9 u 7 cm, dok nije utvrĀeno prisustvo bolesti na
drugim lokalizacijama. Uÿinjeno je kompletno hirurško uklja-
njanje tumorske promene i na osnovu histološkog pregleda
postavljena je dijagnoza difuznog B krupnoýelijskog limfoma,
(DLBCL) non-GCB podtipa. Nakon hirurškog leÿenja pri-
menjen je R-CHOP protokol sa redukovanim dozama adria-
blastina zbog smanjene ejekcione frakcije leve komore. I po-
red veoma lošeg prognostiÿkog profila bolesti (non-GCB tip,
bulky bolesti, visokih vrednosti laktat dehidrogenaze, visokog
komorbiditetnog skora i double-hit fenotipa) bolesnik je veý 20
meseci u kompletnoj remisiji. Conclusion. Imunohemiotera-
pija (R-CHOP) u kombinaciji sa hirurškim leÿenjem je efikas-
na prva linija terapije kod bolesnika sa primarnim adrenalnim
difuznim B-krupnoýelijskim limfomom i pored nepovoljnog
prognostiÿkog profila i double-hit fenotipa bolesti.
Kljuÿne reÿi:
limfom, nehodžkinov; nadbubrežne žlezde,
neoplazme; leÿenje lekovima; hirurgija, operativne
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Introduction
The adrenal gland is a rare site of primary extranodal
non-Hodgkin lymphoma (NHL), accounting for less than 1%
of all NHL cases and only 3% of primary extranodal lym-
phomas 
1. Compared with nodal diffuse large B-cell NHL
(DLBCL), primary adrenal DLBCL is frequently accompa-
nied with many adverse features such as bulky disease, ele-
vated lactate dehydrogenase (LDH), advanced clinical stage
and adrenal insufficiency 
2. Prognosis is poor and most pa-
tients die due to the progressive disease or its complications
within one year after the diagnosis 
3, 4. Double-hit lympho-
mas with MYC and BCL-2 translocation are rare types of
lymphoma (around 2% of NHL) with frequent extranodal
disease and extremely poor prognosis 
5. We presented the
patient with double-hit primary unilateral adrenal lymphoma,
with preserved adrenal function and good outcome.
Case report
A 73-year-old man, with complaints of abdominal pain,
fatigue and weight loss for 4 months was admitted to the
Hematology Department of the Clinical Hospital Center
“Bežanijska kosa”, Belgrade, Serbia. The patient had acute
myocardial infarction in 2007 and underwent gastrectomy
due to bleeding of gastric ulcer 12 years ago. His past medi-
cal history was also significant for alcohol abuse (20 years)
and cigarette smoking (55 years). Hematological analysis
showed mild anemia (hemoglobin level of 103 g/L). Blood
biochemistry showed elevated LDH (920 U/L). Ultrasonog-
raphy and computed tomography (CT) of abdomen demon-
strated 9 u 7 cm mass of the left adrenal gland, without sple-
nomegaly or abdominal lymphadenopathy (Figure 1). The
patient was referred to the Endocrine Surgery Clinic where
left adrenalectomy was done in May 2011.
Histological examination of adrenal tumor revealed di-
agnosis of DLBCL, non-germinal center B-cell (non-GCB)
subtype with following immunephenotype: EMA-, LCA+,
PAX5+, inhibin-, synaptophysin-, CD79+, CD20+, CD5-,
CD3-, CD10-, CD43-, CD30-, CD38-, CD138-, Mum-1+,
BCL2+, BCL6-, ALK-1-, Ki-67 (positive in 60% of lym-
phoma cells). Fluorescence in situ hybridization (FISH)
showed MYC(8q24) and BCL2(18q21) rearrangement (Fig-
ure 2). In June 2011 the patient was referred back to the He-
matology Department. The clinical examination showed pale
skin without superficial lymphadenopathy or organomegaly.
A serum biochemistry profile showed elevated LDH (506
IU/L) and ȕ2 microglobulin of 4.3 mg/L. Serum sodium, po-
tassium and calcium levels were normal. Endocrinology as-
sessment proved that the patient was euthyroid and eucorti-
solemic. Mineralocorticoid function and the function of adre-
nal medulla were also intact. Thoracic CT scan did not show
any lymph node enlargement. CT of brain revealed only a few
old ischemic lesions. Cerebrospinal fluid sediment did not
show any lymphoid cells. Bone marrow trephine biopsy
showed no lymphoid infiltration. Echocardiography showed
reduced ejection fraction (40%) and aneurysmatic dilatation
of the inferior left ventricular wall. Therefore, the patient re-
ceived immunochemotherapy regimen rituximab–cyclophos-
phamide/doxorubicin (hydroxydaunomycin)/vincristine (Onco-
vin
®)/prednisolone (R-CHOP) with reduced doses of an antra-
cycline (doxorubicin 25 mg/m
2 i.v. every 3 weeks). After 6 cy-
cles of R-CHOP chemotherapy the patient was in good condi-
tion with no evidence of tumor on fludeoxyglucose – positron
emission tomography (FDG-PET) scans. The patient was fol-
lowed regularly in our Outpatient Hematology Clinic. On the
Fig. 1 – Computed tomography scan of abdomen
demonstrated 9 u 7 cm mass of the left adrenal gland.
Fig. 2 – MYC (8q24) and BCL2 (18q21) rearrangement (fluorescence in situ hybridisation – FISH).Volumen 71, Broj 7 VOJNOSANITETSKI PREGLED Strana 691
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last follow-up (January, 2013), the patient was in good clinical
condition, with no evidence of lymphoma recurrence.
Discussion
Primary adrenal non-Hodgkin’s lymphoma (PAL) is a
rare neoplasm with approximately 120 cases reported
worldwide 
2. The disease most frequently affects older men
with the mean age of 68 years at diagnosis 
4. The symptoms
of the disease and response to treatment vary depending on
the type of lymphoma, tumor size, and the presence of adre-
nal failure. Literature data based mostly on case reports, re-
vealed a high rate of bilateral involvement (60–79% of
cases) and adrenal failure (67–69% of cases) 
4. Nodal and
extranodal disease in PAL is rare at diagnosis 
6. However,
involvement of unusual extranodal organs is often reported at
the disease relapse 
6. The most frequent histological subtype
of PAL is a diffuse large non-GCB subtype 
2, 7. The pre-
sented patient had typical age, histology and symptoms for
PAL, but he presented without bilateral involvement and
consecutive adrenal failure.
The pathogenesis of PAL is not clear. Immune deregu-
lation may predispose to PAL as well as to certain other
lymphomas in some patients 
8. Proposed hypothesis for the
occurrence of PAL includes preexisting autoimmune adre-
nalitis with lymphocyte infiltration, although not conclu-
sively proven due to the rarity of both autoimmune adrenali-
tis and lymphomas 
9. It is supported by more frequent devel-
opment of adrenal failure in patients with lymphoma than in
patients with bilateral adrenal metastases. Namely, adrenal
failure occurs in 1% of patients with adrenal metastasis and
only when more than 90% of the adrenal tissue is de-
stroyed 
10. In contrast, a very high frequency of primary ad-
renal failure (60–70%) has been reported in patients with
PAL, including patients with mildly enlarged adrenal
glands 
9, 10.
The majority of published cases of PAL had a poor
prognosis, although there were some with good progno-
sis 
3, 4, 11. Poor prognosis is related to bilateral disease, high
International Prognostic Index score, high LDH, the presence
of other localization of disease, non-GCB type and advanced
age 
2. Our patient had double-hit phenotype with concurrent
expression of MYC and BCL2 which is particularly related
to inferior prognosis of DLBCL cases, even in the era of ri-
tuximab 
5, 12–14. Despite non-GCB subtype, double-hit phe-
notype, advanced age, comorbidities and high LDH our pa-
tient achieved complete remission and showed no evidence
of lymphoma recurrence 20 months from the diagnosis.
Given the rarity of PAL, the optimal therapeutic mo-
dality is poorly defined. Available data on outcomes of pa-
tients treated by chemotherapy, unilateral or bilateral adre-
nalectomy, and/or adjuvant radiotherapy gave inconclusive
results 
2, 15–17. In earlier trials of CHOP or CHOP-like ther-
apy, the results of PAL treatment have been disappointing; a
review of the literature data has shown that most patients
died due to the disease or its complications within one year
after diagnosis 
4, 7, 17. In contrast, Kim et al. 
2 have recently
reported that treatment outcomes with R-CHOP for primary
adrenal DLBCL were not inferior to those of nodal DLBCL.
Conclusion
This first published case of double-hit primary adrenal
lymphoma in Serbia suggests that R-CHOP chemotherapy in
combination with adrenalectomy can be an effective first-
line regimen for primary adrenal diffuse large B-cell lym-
phoma, despite the inherently poor prognostic profile and
double-hit phenotype of the disease.
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